We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BARC:LSEBarclays PLC Analysis

Data as of 2026-08-01 - not real-time

£508.70

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Barclays PLC shares have surged to a 19‑year high, trading at 508.7 GBp, just below the 20‑day SMA (516.4) but comfortably above the 50‑day (495.6) and 200‑day (450.7) averages, signalling a bullish trend. The price sits above the identified support at 486 GBp and below a resistance near 538 GBp, offering an upside potential of roughly 12‑13 % based on analyst targets. Momentum indicators are mixed: RSI is neutral at 49.7, while the MACD histogram is negative, hinting at short‑term bearish pressure, yet volume is on an increasing trajectory, reinforcing the recent rally.
Fundamentally, the stock appears undervalued—its trailing PE of 10.6 is well below the industry average of 18, forward PE contracts to 7.9, and the price‑to‑book ratio hovers near 1.0. A dividend yield of 2.26 % with a modest 18 % payout ratio suggests sustainable income. The low beta (~0.68) mitigates market risk, though 30‑day volatility is elevated at ~30 %. Recent stress‑test results for Barclays US LLC were positive, and a consensus of 17 analysts rates the stock as a “buy”, underpinning the optimistic outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at 486 GBp
  • Negative MACD histogram indicating potential pullback
  • High 30‑day volatility (~30 %)

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation metrics (PE 10.6 vs industry 18)
  • Sustainable dividend yield of 2.26 %
  • Forward earnings growth reflected in forward PE of 7.9

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong capital position with cash near debt levels
  • Diversified global operations reducing geographic concentration
  • Positive stress‑test outcomes and broad analyst buy consensus

Key Metrics & Analysis

Financial Health

Revenue Growth15.60%
Profit Margin27.87%
P/E Ratio10.6
ROE10.09%
ROA0.47%
P/B Ratio1.0
Op. Cash Flow£-949000000
Industry P/E18.0

Technical Analysis

TrendBullish
RSI49.7
Support£486.00
Resistance£538.30
MA 20£516.39
MA 50£495.56
MA 200£450.73
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Target Price£572.71
Upside/Downside12.58%
GradeUndervalued
TypeBlend
Dividend Yield2.26%

Risk Assessment

Beta0.68
Volatility30.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.